<div>
  <ul>
    <li>
      <p>
        Massachusetts-based AI-powered gene editing company Arbor Biotechnologies and California-based cell therapy company Allogene Therapeutics have entered a non-exclusive, global gene-editing licensing agreement to treat autoimmune disease.
      </p>
    </li>
    <li>
      <p>
        Under the terms of the agreement, Arbor's CRISPR gene-editing technology will be integrated into Allogene's AlloCAR T platform to develop a widely applicable Chimeric Antigen Receptor T-cell (CAR T) treatment for autoimmune disease. Allogene's AlloCAR T product for autoimmune ailments is expected to undergo Phase I clinical trials in early 2025.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://arbor.bio/allogene-therapeutics-and-arbor-biotechnologies-announce-global-gene-editing-licensing-agreement-to-support-advancement-of-next-generation-allogeneic-car-t-platform-in-autoimmune-disease/">
      Press release
    </a>
  </p>
  <p>
    <a href="https://markets.businessinsider.com/news/stocks/allogene-arbor-announce-global-gene-editing-licensing-agreement-for-car-t-platform-1033155162">
      Marker Business Insider
    </a>
  </p>
</div>


Human Gene Editing

PROMINENT_CATEGORY

<div>
 <p>Arbor Biotechnologies, a Massachusetts-based AI-powered gene editing company, and Allogene Therapeutics, a California-based cell therapy company, have signed a non-exclusive, global licensing agreement to develop gene-editing treatments for autoimmune diseases. The agreement will see the integration of Arbor's CRISPR gene-editing technology into Allogene's AlloCAR T platform.</p>
 <p>This cooperation aims to create a widely applicable Chimeric Antigen Receptor T-cell (CAR T) treatment for autoimmune disease. Allogene's AlloCAR T product for autoimmune conditions is projected to commence Phase I clinical trials in early 2025.</p>
 
</div>

Arbor Biotechnologies and Allogene Therapeutics announce global gene-editing licensing agreement to treat CAR T autoimmune disease

Artificial intelligence is identifying and testing new therapies faster than ever.

All Updates

Arbor Biotechnologies and Allogene Therapeutics announce global gene-editing licensing agreement to treat CAR T autoimmune disease

Arbor Biotechnologies and Vertex Pharmaceuticals partner to develop genetic medicines

Arbor Biotechnologies and Vertex Pharmaceuticals partner to develop genetic medicines